Fesoterodine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fesoterodine
Fesoterodine.svg
Systematic (IUPAC) name
[2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
Clinical data
Trade names Toviaz
AHFS/Drugs.com monograph
MedlinePlus a609021
Licence data EMA:Link, US FDA:link
Pregnancy cat. C (US)
Legal status Prescription only
Routes Oral
Pharmacokinetic data
Bioavailability 52% (active metabolite)
Protein binding 50% (active metabolite)
Metabolism Hepatic (CYP2D6- and 3A4-mediated)
Half-life 7–8 hours (active metabolite)
Excretion Renal (70%) and fecal (7%)
Identifiers
CAS number 286930-03-8 N
ATC code G04BD11
PubChem CID 6918558
DrugBank DB06702
ChemSpider 5293755 YesY
UNII 621G617227 YesY
KEGG D07226 YesY
ChEMBL CHEMBL1201764 N
Chemical data
Formula C26H37NO3 
Mol. mass 411.278 g/mol
 N (what is this?)  (verify)

Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007,[2] the US Food and Drug Administration on October 31, 2008 [3] and Health Canada on February 9, 2012.[4]

Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.

Efficacy[edit]

Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists.[5] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.[5]

References[edit]